Brokerages Set Vor Biopharma Inc. (NASDAQ:VOR) Target Price at $43.38

Vor Biopharma Inc. (NASDAQ:VOR) has earned an average rating of “Moderate Buy” from the eleven research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $43.3750.

A number of analysts have issued reports on the company. Wedbush lifted their price target on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, August 12th. Wall Street Zen upgraded Vor Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. HC Wainwright restated a “buy” rating and set a $31.00 target price on shares of Vor Biopharma in a research note on Monday, May 18th. Finally, Weiss Ratings raised Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a report on Tuesday, August 11th.

Vor Biopharma Stock Up 3.3%

Vor Biopharma stock opened at $25.05 on Thursday. The company has a fifty day simple moving average of $21.28 and a 200-day simple moving average of $17.07. Vor Biopharma has a 12-month low of $6.50 and a 12-month high of $49.95.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). On average, equities research analysts expect that Vor Biopharma will post -2.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of VOR. RA Capital Management L.P. raised its stake in Vor Biopharma by 172.7% during the 4th quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock worth $70,697,000 after acquiring an additional 3,422,697 shares in the last quarter. Fcpm Iii Services B.V. boosted its stake in Vor Biopharma by 852.8% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after acquiring an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new position in Vor Biopharma in the fourth quarter valued at $33,275,000. Paradigm Biocapital Advisors LP purchased a new position in shares of Vor Biopharma during the fourth quarter worth about $22,890,000. Finally, NEXTBio Capital Management LP purchased a new position in shares of Vor Biopharma during the fourth quarter worth about $13,080,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).